Rezolute, Inc.
Rezolute, Inc. (Nasdaq: RZLT) is a late-stage rare disease biotechnology company developing therapies for refractory hypoglycemia associated with hyperinsulinism. Its lead candidate, ersodetug, is an intravenous monoclonal antibody designed to reduce insulin-receptor activity, and is being studied for congenital… From the company’s description.
In fiscal 2026, Rezolute, Inc. reported a net loss of $77.59M. Operations used $64.64M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rezolute, Inc. does
In the company’s own words
Rezolute, Inc. (Nasdaq: RZLT) is a late-stage rare disease biotechnology company developing therapies for refractory hypoglycemia associated with hyperinsulinism. Its lead candidate, ersodetug, is an intravenous monoclonal antibody designed to reduce insulin-receptor activity, and is being studied for congenital hyperinsulinism and tumor-related hyperinsulinism, including hypoglycemia associated with insulinomas and other tumors. The company’s Phase 3 sunRIZE study in congenital hyperinsulinism did not meet its primary or key secondary endpoint; the FDA is reviewing additional analyses to assess a potential regulatory path. In the Phase 3 upLIFT study for tumor-related hyperinsulinism, ersodetug is being evaluated in a single-arm trial of patients requiring continuous intravenous glucose. Rezolute also provides ersodetug through expanded access programs for patients with refractory forms of hyperinsulinism who cannot access a clinical trial. The company has no marketed products and reports no business segments. It had 58 full-time employees as of June 30, 2026, and incurred $53.8 million in research and development expense in fiscal 2026. Its website is www.rezolutebio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- June
- CIK
- 1509261
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rezolute, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rezolute, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rezolute, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rezolute, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rezolute, Inc.'s last four quarterly filings that the numbers alone won't show?”